
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


STAAR Surgical Company (STAA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: STAA (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $19.1
1 Year Target Price $19.1
3 | Strong Buy |
0 | Buy |
10 | Hold |
0 | Sell |
1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.16% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 837.98M USD | Price to earnings Ratio - | 1Y Target Price 19.1 |
Price to earnings Ratio - | 1Y Target Price 19.1 | ||
Volume (30-day avg) 14 | Beta 0.61 | 52 Weeks Range 13.50 - 49.86 | Updated Date 06/30/2025 |
52 Weeks Range 13.50 - 49.86 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -25.46% | Operating Margin (TTM) -81.43% |
Management Effectiveness
Return on Assets (TTM) -5.9% | Return on Equity (TTM) -19.14% |
Valuation
Trailing PE - | Forward PE 625 | Enterprise Value 651403841 | Price to Sales(TTM) 3 |
Enterprise Value 651403841 | Price to Sales(TTM) 3 | ||
Enterprise Value to Revenue 2.33 | Enterprise Value to EBITDA 42.84 | Shares Outstanding 49526100 | Shares Floating 30182860 |
Shares Outstanding 49526100 | Shares Floating 30182860 | ||
Percent Insiders 0.64 | Percent Institutions 109.46 |
Analyst Ratings
Rating 4 | Target Price 19.1 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 10 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
STAAR Surgical Company

Company Overview
History and Background
STAAR Surgical Company was founded in 1982. It focuses on the design, development, manufacture, and marketing of implantable lenses for the eye. A significant milestone includes FDA approval for its Visian ICL (Implantable Collamer Lens). The company has evolved from offering a broader range of ophthalmic products to focusing on refractive lenses.
Core Business Areas
- Implantable Lenses: This segment involves the manufacturing and sale of implantable lenses (ICLs) for the correction of myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. This is STAAR's primary revenue driver.
- Other Ophthalmic Products: This smaller segment includes other surgical products, such as phacoemulsification products used in cataract surgery.
Leadership and Structure
STAAR Surgical Company is led by Tom Frinzi (President and CEO). The organizational structure includes departments for Research and Development, Manufacturing, Sales and Marketing, Finance, and Operations.
Top Products and Market Share
Key Offerings
- Visian ICL: The Visian ICL is STAAR Surgical's flagship product, an implantable collamer lens used for correcting myopia, hyperopia, and astigmatism. Market share estimates vary but STAAR is estimated to hold 20% of the market. Revenue is centered around this product, but exact data is not publicly available. Competitors include Johnson & Johnson Vision, Alcon, and Carl Zeiss Meditec.
- Toric ICL: The Toric ICL is a variation of the Visian ICL designed to correct astigmatism along with myopia or hyperopia. Market share is likely included within the overall ICL market share. Competitors are the same as for Visian ICL
Market Dynamics
Industry Overview
The ophthalmic surgical market is driven by an aging population, increasing prevalence of refractive errors, and technological advancements. It is competitive with key players focusing on innovation in surgical procedures and devices.
Positioning
STAAR Surgical Company holds a strong position in the refractive lens market, particularly with its ICL technology. Its competitive advantages include its proprietary Collamer material and its minimally invasive surgical procedure.
Total Addressable Market (TAM)
The global refractive surgery market is expected to reach approximately $6.0 billion to $7.0 billion, with STAAR Surgical Company targeting a significant portion of this market through its ICL products. They are positioned to continue growing within this market.
Upturn SWOT Analysis
Strengths
- Proprietary Collamer Material
- Minimally Invasive Surgical Procedure
- Strong Brand Recognition (Visian ICL)
- Focus on Refractive Lenses
- Growing Global Presence
Weaknesses
- Reliance on a Single Product Category (ICL)
- Smaller Market Share Compared to Larger Competitors
- Geographic Concentration of Sales
- Manufacturing Capacity Limitations
Opportunities
- Expanding into New Geographies
- Developing New ICL Models (e.g., for Presbyopia)
- Increasing Awareness of ICL Technology
- Strategic Partnerships with Ophthalmic Surgeons
- Capturing a larger portion of the TAM through increased market awareness
Threats
- Competition from Laser Vision Correction (LASIK, SMILE)
- Technological Advancements by Competitors
- Economic Downturns Affecting Elective Procedures
- Regulatory Changes in Key Markets
- Supply Chain Disruptions
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- CAJZY
Competitive Landscape
STAAR Surgical Company faces competition from larger, more diversified ophthalmic companies. Its competitive advantages include its proprietary Collamer material and its focus on ICL technology. However, it needs to address its reliance on a single product category and manufacturing capacity limitations.
Growth Trajectory and Initiatives
Historical Growth: STAAR Surgical has experienced significant growth in recent years, driven by increasing ICL sales and expanding global presence.
Future Projections: Analyst estimates project continued revenue growth for STAAR Surgical, supported by increasing demand for ICL products and geographic expansion. However, growth rates are expected to moderate as the company scales.
Recent Initiatives: Recent strategic initiatives include expanding sales and marketing efforts in key markets, investing in R&D for new ICL models, and optimizing manufacturing capacity.
Summary
STAAR Surgical is a growing company with strong revenue increases centered on its ICL product line. Its proprietary technology and minimally invasive procedure give them a competitive edge. They should be wary of competitors innovating in laser vision correction and capacity limits on manufacturing. STAAR Surgical is positioned for continued growth as long as they meet the demand.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share figures are estimates and may vary. Forward looking statements cannot be gauranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STAAR Surgical Company
Exchange NASDAQ | Headquaters Lake Forest, CA, United States | ||
IPO Launch date 1983-07-15 | CEO & Director Mr. Stephen C. Farrell CFA | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1157 | Website https://www.staar.com |
Full time employees 1157 | Website https://www.staar.com |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.